Amgen Psoriasis Candidate Impresses
The New England Journal of Medicine recently published positive phase II data on Amgen’s (NASDAQ:AMGN) psoriasis candidate, brodalumab (formerly known as AMG 827). Results from the 12-week randomized, double-blind, placebo-controlled, dose-ranging phase II study, conducted with 198 patients suffering from moderate-to-severe plaque psoriasis, showed that brodalumab achieved its primary endpoint. The mean percentage improvement in [...]
The New England Journal of Medicine recently published positive phase II data on Amgen’s (NASDAQ:AMGN) psoriasis candidate, brodalumab (formerly known as AMG 827).
Results from the 12-week randomized, double-blind, placebo-controlled, dose-ranging phase II study, conducted with 198 patients suffering from moderate-to-severe plaque psoriasis, showed that brodalumab achieved its primary endpoint. The mean percentage improvement in psoriasis area and severity index (PASI) was higher in all brodalumab … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards